NCT06978738尚未招募1 期
A Clinical Study Evaluating the Safety and Preliminary Efficacy of Universal Allogeneic CAR T-cell Therapy Targeting CD19 and BCMA in Patients With Relapse/Refractory Autoimmune Diseases
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 尚未招募
- 入组人数
- 18
- 试验地点
- 1
- 主要终点
- The number and severity of dose-limiting toxicity (DLT) events
研究概览
简要总结
This is an investigator-initiated trial to evaluate the safety and efficacy of universal allogeneic anti-CD19/BCMA CAR T-cells in With Relapse/Refractory Autoimmune Diseases.
详细描述
This is an investigator-initiated trial to evaluate the safety and efficacy ofuniversal allogeneic anti-CD19/BCMA CAR T-cells in Patients With Relapse/Refractory Autoimmune Diseases.
Study intervention consists of a single infusion of universal allogeneic CART-cells administered intravenously after a lymphodepleting therapy regimen consisting of fludarabine and cyclophosphamide.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •1.Age ≥ 18 years old (inclusive), regardless of gender.
- •2.Positive expression of CD19 on peripheral blood B cells confirmed by flow cytometry.
- •3.Functional requirements for major organs are as follows:
- •Bone marrow function must meet: A. Neutrophil count ≥ 0.5×10 ^ 9/L (no colony-stimulating factor treatment within 2 weeks before examination); B. Hemoglobin ≥ 60g/L; C. Platelets ≥ 30 × 10 ^ 9/L.
- •Liver function: Alanine aminotransferase (ALT) ≤ 3×ULN (excluding ALT elevation due to inflammatory myopathy), aspartate aminotransferase (AST)≤3×Upper limit of normal (ULN) (excluding AST elevation due to inflammatory myopathy), TBIL≤1.5×ULN (or ≤ 3.0×ULN for subjects with Gilbert syndrome);
- •Renal function: creatinine clearance rate (CrCl) ≥ 30ml/minute (calculated by Cockcroft/Gault formula, acute CrCl decrease due to the target disease is excluded; LN is exluded);
- •4.ECOG score 0-
- •5.Female subjects of childbearing potential and male subjects with partners of childbearing potential must use medically approved contraception or abstinence during the study treatment period and for at least 6 months after the end of the study treatment; Female subjects of childbearing potential must have a negative Human chorionic gonadotropin (HCG) test within 7 days before study enrollment and not be lactating.
- •6.Willing to participate in this clinical study, sign an informed consent form, have good compliance, and cooperate with follow-up.
- •7.Subjects with relapsed or refractory autoimmune diseases, Including relapsed or refractory Autoimmune Hemolytic Anemia, relapsed or refractory Systemic Lupus Erythematosus, relapsed or refractory or Progressive Systemic Sclerosis, relapsed or refractory or Progressive Inflammatory Myopathy, relapsed or refractory ANCA-Associated Vasculitis, relapsed or refractory Immunoglobulin-G4 related disease and relapsed or refractory Myasthenia Gravis.
排除标准
- •1.Subjects with a history of severe drug allergies or allergic constitutions;
- •Presence or suspicion of uncontrolled or treatment-required fungal, bacterial, viral, or other infections;
- •Subjects with insufficient cardiac function;
- •Subjects with congenital immunoglobulin deficiencies;
- •Subjects with a history of malignant tumors within the past five years, except for the following conditions: non-melanoma skin cancer, stage I tumors with a low recurrence probability after complete resection, clinically localized prostate cancer after treatment, cervical carcinoma in situ confirmed by biopsy or squamous intraepithelial lesion shown by smear, and stable papillary thyroid carcinoma or follicular thyroid carcinoma.
- •Subjects who are positive for hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb) with peripheral blood HBV DNA >ULN; subjects positive for hepatitis C virus (HCV) antibody and peripheral blood HCV RNA; individuals positive for human immunodeficiency virus (HIV) antibody; individuals positive for syphilis testing;
- •Subjects with mental illness and severe cognitive dysfunction;
- •Pregnant women or women planning to conceive;
- •9.Subjects whom the investigator believes have other reasons that make them unsuitable for inclusion in this study.
研究组 & 干预措施
UCAR T-cell group
Experimental
A single injection of UCAR T-cells, referred to as universal allogeneic anti-CD19/BCMA CAR T-cells
干预措施: universal allogeneic anti-CD19/BCMA CAR T-cells (Biological)
结局指标
主要结局
The number and severity of dose-limiting toxicity (DLT) events
时间窗: Within 28 Days After UCAR T-cell Infusion
DLT will be graded according to the NCI Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0, and the ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells.
The total number, incidence, and severity of AEs
时间窗: Up to 90 days After UCAR T-cell Infusion
次要结局
- AIHA：Rates of CR, CRi, PR, ORR(Up to 24 Months After UCAR T-cell Infusion)
- SLE：SLE Response Index 4 (SRI-4)(Up to 24 Months After UCAR T-cell Infusion)
- SLE: Change in the Systemic Lupus Erythematosus Disease Activity Index(SLEDAI) from baseline(Up to 24 Months After UCAR T-cell Infusion)
- SSc：Change in the modified Rodnan Skin Score (mRSS) from baseline(Up to 24 Months After UCAR T-cell Infusion)
- IIM：The ACR-EULAR Myositis Response Criteria [Total Improvement Score (TIS)](Up to 24 Months After UCAR T-cell Infusion)
- AAV: Change in disease activity as measured by Birmingham Vasculitis Activity Score (BVAS)(Up to 24 Months After UCAR T-cell Infusion)
- IgG4-RD:IgG4-Related Disease Responder Index (IgG4-RD RI)(Up to 24 Months After UCAR T-cell Infusion)
- MG:Changes of Myasthenia Gravis Activities of Daily Living (MG-ADL) Score(Up to 24 Months After UCAR T-cell Infusion)
- MG:Quantitative Myasthenia Gravis Score (QMG)(Up to 24 Months After UCAR T-cell Infusion)
研究者
Lu Xuzhang
Principal Investigator
Changzhou No.2 People's Hospital
研究点 (1)
Loading locations...
相似试验
招募中
1 期
CAR T-cell Therapy Targeting CD19 and BCMA in Patients with AIHA Who Have Failed ≥3 Lines of Therapy.CD19/BCMA CAR T-cellsUniversal Allogeneic CAR T-cellsAutoimmune Hemolytic AnemiaNCT06733610Institute of Hematology & Blood Diseases Hospital, China15
已完成
1 期
Stem Cell Injection in Cancer SurvivorsCardiomyopathy Due to AnthracyclinesNCT02509156The University of Texas Health Science Center, Houston46
招募中
早期 1 期
Allogeneic CD19-targeted CAR-γδT Cell Infusion Therapy in Relapsed/Refractory B Cell Acute Lymphoblastic LeukemiaB-Cell Acute Lymphoblastic Leukemia, AdultNCT06696833The First Affiliated Hospital of Soochow University18
招募中
早期 1 期
UTAA09 Injection in the Treatment of Relapsed/Refractory Hematolymphatic Malignancies.CD19-positive Relapsed or Refractory B-cell MalignanciesNCT06092047PersonGen BioTherapeutics (Suzhou) Co., Ltd.10
已完成
2 期
Allogeneic Mesenchymal Stem Cell Transplantation in Tibial Closed Diaphyseal FracturesTibial FractureNCT02140528Royan Institute40